Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + sorafenib first-line treatment biomarker study in advanced hepatocellular carcinoma
ChiCTR2000031195Phase 3Recruiting
- Sponsor
- The first hospital affliated to the USTC
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sintilimab and sorafenib in hepatocellular carcinoma (HCC), sponsored by The first hospital affliated to the USTC. Primary endpoints: Lymphocyte subsets analysis and Single-cell sequencing. Started Jan 2021; status: recruiting.
02
Drugs
sintilimabsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000031195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031195.